Renal Cell Carcinoma

PD-L1 expression in tumors is a candidate molecular marker warranting further investigation as a means to select patients for immunotherapy with an anti PD-1 antibody

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the outlook for immunotherapies in cancer care.

AGS-003, an investigational autologous dendritic cell vaccine, successfully activated a cytotoxic T cell response that correlates with a prolongation in survival for patients with metastatic renal cell carcinoma (mRCC), according to an analysis presented at the 2013 Annual Meeting of the Society for Immunotherapy of Cancer.

The treatment of advanced renal cell carcinoma (RCC) remains a major challenge for clinicians. However, according Daniel J. George, MD, the progress being made in understanding RCC tumor biology is already helping us to discover better, more effective treatments.

Targeted Oncology spoke with Shilpa Gupta, MD, from the Moffitt Cancer Center and University of South Florida Morisani College of Medicine, on considerations in choice of therapy for first-line treatment of mRCC.

Jeffrey A. Sosman, MD, professor of medicine, director, Melanoma and Tumor Immunotherapy Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, discusses immune response in renal cell carcinoma.

James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan-Kettering Cancer Center, discusses the frontline treatment of patients with kidney cancer with pazopanib and sunitinib.

Though pazopanib and sunitinib are relatively similar in terms of efficacy in the treatment of advanced renal cell carcinoma, the former appears to cause fewer toxic side effects than the latter, suggesting that patients could experience a greater quality of life and the same treatment benefit with pazopanib as opposed to sunitinib.

With seven targeted therapies approved for metastatic renal cell carcinoma (RCC), researchers and drug developers are now focusing on understanding the best way to sequence these therapies—and on identifying predictive biomarkers of response.

Over the past two decades, there has been a shift away from indiscriminate cell-killing by anticancer agents toward the development of more specific drugs that target key aspects of cancer cell biology.

Paul A. Bunn, Jr, MD, from the University of Colorado, discusses afatinib for patients with activating epidermal growth factor receptor mutation.

Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the difficulties with a gold standard clinical trial endpoint in ovarian cancer.

Pazopanib was better tolerated with noninferior efficacy when compared to sunitinib as a treatment for patients with advanced renal cell carcinoma.

The standard of care for metastatic renal-cell carcinoma (RCC) prevailed in a randomized comparison of everolimus and sunitinib as first-line therapy.

Renier J. Brentjens, MD, PhD, from Memorial Sloan-Kettering Cancer Center, discusses the potential efficacy of CAR-modified T cells for the treatment of solid tumors.

At the 18th Annual Conference of the National Comprehensive Cancer Network (NCCN), experts presented the latest updates to the NCCN Clinical Practice Guidelines in Oncology.

Cameron J. Turtle, MD, PhD, from the Fred Hutchinson Cancer Research Center, discusses the design of a chimeric antigen receptor (CAR).

Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, discusses PD-1 and PD-L1 in various cancers.

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, UCLA, describes the development of cyclin-dependent kinases (CDKs) for the treatment of cancer.

Researchers at the NCI have developed the most comprehensive analysis of coding variants in the most frequently studied human tumor cell lines in cancer research.

The FDA rejected a new drug application for tivozanib, an inhibitor of vascular endothelial growth factor (VEGF), for the treatment of advanced renal cell carcinoma (RCC).

Sorafenib is small molecule inhibitor approved for the treatment of primary kidney cancer and advanced primary liver cancer.